Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jul;34(7):1318–1322. doi: 10.1128/aac.34.7.1318

Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.

W L Hayton 1, J Kneer 1, R A Blouin 1, K Stoeckel 1
PMCID: PMC175973  PMID: 2386364

Abstract

The pharmacokinetics of orally administered cefetamet pivoxil and intravenously administered cefetamet were studied in 12 healthy subjects and 12 patients with hepatic cirrhosis without ascites. Cirrhosis had no detectable effect on the pharmacokinetics of cefetamet and on the bioavailability of cefetamet pivoxil. After intravenous cefetamet in control versus cirrhotic subjects, respectively, the following mean +/- standard deviation values were observed: total body clearance, 128 +/- 10.2 versus 123 +/- 28.8 ml/min; steady-state volume of distribution, 23.2 +/- 2.2 versus 22.7 +/- 4.6 liters; half-life, 2.42 +/- 0.21 versus 2.35 +/- 0.41 h. Renal and nonrenal clearances of cefetamet were similar in both groups, as were the mean residence times and areas under the plasma concentration-time curve. For oral cefetamet pivoxil, no differences were detected in the mean values of the percentage of dose absorbed: 44.6 +/- 9.1 versus 50.1 +/- 12.9. The rate of appearance of cefetamet in the plasma also was not affected by cirrhosis: similar mean values were found for the mean residence time and the maximum concentration in plasma and its time of occurrence.

Full text

PDF
1318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre J., Mallat A., Rosenbaum J., Deforges L., Houin G., Dhumeaux D., Tillement J. P. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753–757. doi: 10.1111/j.1365-2125.1987.tb03111.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blouin R. A., Kneer J., Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother. 1989 Mar;33(3):291–296. doi: 10.1128/aac.33.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cardey J., Silvain C., Bouquet S., Breux J. P., Becq-Giraudon B., Fourtillan J. P., Beauchant M. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. Eur J Clin Pharmacol. 1987;33(5):469–472. doi: 10.1007/BF00544237. [DOI] [PubMed] [Google Scholar]
  4. Colli A., Buccino G., Cocciolo M., Parravicini R., Scaltrini G. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clin Pharmacol Ther. 1988 Dec;44(6):642–649. doi: 10.1038/clpt.1988.206. [DOI] [PubMed] [Google Scholar]
  5. Danan G., Montay G., Cunci R., Erlinger S. Pefloxacin kinetics in cirrhosis. Clin Pharmacol Ther. 1985 Oct;38(4):439–442. doi: 10.1038/clpt.1985.201. [DOI] [PubMed] [Google Scholar]
  6. Frost R. W., Lettieri J. T., Krol G., Shamblen E. C., Lasseter K. C. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin Pharmacol Ther. 1989 Jun;45(6):608–616. doi: 10.1038/clpt.1989.81. [DOI] [PubMed] [Google Scholar]
  7. Hary L., Andrejak M., Leleu S., Orfila J., Capron J. P. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol. 1989;36(6):613–616. doi: 10.1007/BF00637745. [DOI] [PubMed] [Google Scholar]
  8. Höffken G., Lode H., Koeppe P., Ruhnke M., Borner K. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy. 1984;30(1):7–17. doi: 10.1159/000238238. [DOI] [PubMed] [Google Scholar]
  9. Kawasaki S., Sugiyama Y., Iga T., Hanano M., Beppu T., Sugiura M., Sanjo K., Idezuki Y. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther. 1988 Aug;44(2):217–224. doi: 10.1038/clpt.1988.140. [DOI] [PubMed] [Google Scholar]
  10. Kneer J., Tam Y. K., Blouin R. A., Frey F. J., Keller E., Stathakis C., Luginbuehl B., Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother. 1989 Nov;33(11):1952–1957. doi: 10.1128/aac.33.11.1952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Koup J. R., Dubach U. C., Brandt R., Wyss R., Stoeckel K. Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother. 1988 Apr;32(4):573–579. doi: 10.1128/aac.32.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MacLeod C. M., Bartley E. A., Payne J. A., Hudes E., Vernam K., Devlin R. G. Effects of cirrhosis on kinetics of aztreonam. Antimicrob Agents Chemother. 1984 Oct;26(4):493–497. doi: 10.1128/aac.26.4.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ohashi K., Tsunoo M., Tsuneoka K. Pharmacokinetics and protein binding of cefazolin and cephalothin in patients with cirrhosis. J Antimicrob Chemother. 1986 Mar;17(3):347–351. doi: 10.1093/jac/17.3.347. [DOI] [PubMed] [Google Scholar]
  14. Pauwels S., Geubel A. P., Dive C., Beckers C. Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci. 1982 Jan;27(1):49–56. doi: 10.1007/BF01308121. [DOI] [PubMed] [Google Scholar]
  15. Saudek F., Morávek J., Modr Z. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test. Int J Clin Pharmacol Ther Toxicol. 1989 Feb;27(2):82–87. [PubMed] [Google Scholar]
  16. Schneider J. F., Baker A. L., Haines N. W., Hatfield G., Boyer J. L. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology. 1980 Dec;79(6):1145–1150. [PubMed] [Google Scholar]
  17. Stoeckel K., Tuerk H., Trueb V., McNamara P. J. Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther. 1984 Oct;36(4):500–509. doi: 10.1038/clpt.1984.210. [DOI] [PubMed] [Google Scholar]
  18. Tam Y. K., Kneer J., Dubach U. C., Stoeckel K. Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother. 1989 Jun;33(6):957–959. doi: 10.1128/aac.33.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vincent P., Colombel J. F., Husson M. O., Izard D., Paris J. C., Leclerc H. Pharmacocinétique du céfotaxime chez les malades cirrhotiques avec ou sans ascite. Presse Med. 1988 Dec 10;17(44):2331–2334. [PubMed] [Google Scholar]
  20. Wyss R., Bucheli F. Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography. J Chromatogr. 1988 Aug 19;430(1):81–92. doi: 10.1016/s0378-4347(00)83136-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES